Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Estimates By $0.18 EPS

Vir Biotechnology (NASDAQ:VIR) announced its quarterly earnings data on Wednesday. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.18, FiscalAI reports. The company had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.98 million.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta phase III results are approaching: Vir expects ECLIPSE 1 top-line data in Q4 2026, followed by ECLIPSE 2 and 3 in Q1 2027. The trials assess its combination regimen in treatment-naïve patients, patients switching from bulevirtide, and a head-to-head comparison with bulevirtide; management believes the program could offer deep viral suppression and less frequent dosing.
• VIR-5500 advanced toward pivotal development: Astellas and Vir say the prostate cancer T-cell engager achieved proof of concept based on combined clinical, safety, pharmacology, and biomarker data, and the FDA granted it fast-track designation for late-line mCRPC. The companies aim to begin multiple phase III studies in 2027, though Vir did not disclose response durability or detailed trial plans.
• Gilead collaboration adds funding and validates Vir’s platform: Vir received $65 million upfront plus a $25 million equity investment at a 30% premium, and is eligible for $45 million in near-term preclinical milestones, up to $1.74 billion in additional milestones, and tiered royalties. Gilead will take responsibility for later development, manufacturing, and commercialization of candidates; milestone and royalty payments are contingent.
• Vir reported $901 million in cash, equivalents, and investments at quarter-end, excluding the $90 million Gilead payment received in October. Management expects its cash to fund operations into the second half of 2028, based on its current operating plan.
• VIR-5818’s data update has been pushed out: Following FDA feedback on the monotherapy arm, Vir plans to add backfill cohorts in a more homogeneous patient population to refine dose and schedule. The study remains ongoing and the data set is incomplete, although combination dose optimization continues.

Vir Biotechnology Stock Performance

NASDAQ VIR traded up $0.55 during trading hours on Wednesday, hitting $11.77. The company had a trading volume of 2,804,681 shares, compared to its average volume of 2,362,147. The business has a 50 day moving average of $10.99 and a 200-day moving average of $9.53. The company has a market cap of $1.99 billion, a PE ratio of -6.33 and a beta of 1.70. Vir Biotechnology has a 1-year low of $4.82 and a 1-year high of $12.19.

Insider Activity at Vir Biotechnology

In other news, EVP Vanina de Verneuil sold 2,407 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the sale, the executive vice president directly owned 110,193 shares of the company’s stock, valued at approximately $1,223,142.30. The trade was a 2.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on VIR. HC Wainwright boosted their price target on shares of Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, October 2nd. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a report on Thursday, August 6th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vir Biotechnology in a research report on Monday, September 28th. Finally, Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.